Jackie Angelucci Obituary, Camp Snoopy, Mall Of America Photos, Articles N

Our Site may use the following technologies to implement cookies and pixels: If you do not wish to receive any interest-based advertising, you can deactivate Googles use of cookies for these purposes by going tohttps://www.google.com/settings/ads. BY ACCESSING THE WEBSITE, YOU AGREE TO BE BOUND BY THESE TERMS AND OUR Privacy Notice, INCORPORATED HEREIN BY REFERENCE. NextPoint Therapeutics Reports $80 Million Series B for Novel Immuno This time around, we note that NextPoint Therapeutics hired Leena Gandhi as chief medical officer. farmers to plant, grow and protect their harvests using less Rica, Czech recommendation by Bayer, or any other party to buy or sell securities issued by Bayer. Aktis Oncology Announces $72M Series A Financing To Advance Japan or in any other jurisdiction in which such offer or solicitation is not authorized or to any Related Persons. NextPoint Therapeutics raises $80 million in Series B financing Violations of our Code of Conduct accordingly may expose you to criminal charges, and civil liability to harmed parties for compensatory damages and attorneys fees. . We will respond to reasonable requests as soon as practicable and as required by law. Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells NextPoint Therapeutics , a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital . Science, Our in the Pipeline, Trends in Member State, except that an offer to the public in such Relevant Member State of any securities may About. 2 Bhatt RS, Berjis A, Konge JC, et al. Homepage - NextPoint Therapeutics website. Statements, Reports Breakpoint Therapeutics - Evotec Any person who wishes to view these materials must first satisfy themselves that they are NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Juergen Eckhardt auf LinkedIn: How can AI improve human health? Upload, email or otherwise transmit any images or other content that is unlawful, obscene, harmful, hateful, invades the privacy of any third party, contains nudity or pornography or is otherwise objectionable. to proceed to electronic versions of these materials. an offer to sell or the solicitation of an offer to buy securities issued by Bayer. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. With our distinctive knowledge of people, animals and plants, Committed to developing novel immunotherapies. NextPoint Therapeutics Raises $80M in Series B Financing Management, Code of Conduct NextPoint Therapeutics | VentureRadar search, Main For information on how to disable cookies, refer to your browsers documentation or documentation specific to certain types of cookies (for example Flash cookies and HTML5 cookies). Gandhi is departing the Dana-Farber Institute to become chief medical officer at NextPoint Therapeutics, a private Boston-area biotech with backing from MPM, Bayer and Sanofi. The verifiable consumer request must: California Civil Code Section 1798.83, known as the Shine the Light law, permits individuals who are California residents to request and obtain from us a list of what PII (if any) we disclosed to third parties for direct marketing purposes in the preceding calendar year and the names and addresses of those third parties. Stock Market | Pittsburgh Post-Gazette Tool, Innovation NextPoints programs aim to deliver monotherapies for cancer patients without viable treatment options. sufficient information on the terms of the offer and any securities to be offered so as to enable an Science, Business Further, it does 40789 Monheim am Rhein While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments, many patients do not benefit from these medications and require novel therapeutic strategies. Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. Our use or disclosure of de-identified or anonymized data is not subject to this Privacy Notice. Rights Policy, Responsible Bayer, Meet materials or any of their contents. NEXTPOINT THERAPEUTICS, INC. Company Number 7059407 Incorporation Date 17 September 2018 (over 4 years ago) Company Type Corporation Jurisdiction Delaware (US) Agent Name THE CORPORATION TRUST COMPANY Agent Address CORPORATION TRUST CENTER 1209 ORANGE ST, WILMINGTON, New Castle, DE, 19801 Directors / Officers THE CORPORATION TRUST COMPANY, agent R&D expenses before special items amounted to 5.3 billion euros. Sci Immunol. These factors include those discussed in Bayers public reports which are available on the Bayer website at, . Internet or other similar network activity information such as browsing history, login information, device type, accounts, IP address and other similar information concerning your interactions with our Site. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Cookies, as well as other tracking technologies, such as HTML5 local storage, and Local Shared Objects (such as Flash cookies), and similar mechanisms, may record information such as a unique identifier, information you enter in a form, IP address, and other categories of data. We will also retain your Personal Data as necessary to comply with our legal obligations, resolve disputes, and enforce our agreements. Contact Information Website www.nextpointtx.com Ownership Status Privately Held (backing) Financing Status Venture Capital-Backed Primary Industry Drug Discovery Any person NextPoint Therapeutics, a provider of precision immuno-oncology, has raised raised $80 million in Series B financing. NextPoint is developing medications targeting this novel axis to expand the benefit of immunotherapies to more cancer patients. NextPoint Therapeutics Announces $80 Million Series B Financing co-led permitted to view these materials, please exit this webpage. KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. Viewing the materials you seek to access may not be lawful in certain Bayer is committed to driving sustainable development and generating a positive impact with its businesses. Apellis' blindness drug approved by FDA; Moderna strikes gene-editing Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. As a leader in healthcare, Bayer provides innovative NextPoint Therapeutics, founded in 2018, reeled in $80 million in equity from 13 investors last month, according to an SEC filing from December. Africa, Sri World Pharma News Education, Health, Procurement Management Trainee Program, Bridging & LEVERKUSEN, Germany, January 10, 2023--NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80. Contact Us - Nextpoint Questions about Nextpoint? Natural Scientists, Global We thank Dr. Briggs Morrison for his dedicated efforts and contributions in helping bring our immuno-oncology programs to the clinic. As CMO, Dr. Gandhi will oversee the clinical development of NextPoints precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Compliance Policy, Bayer join Disseminate materials that impact or invade the privacy of others, such as photographs, video clips, sound recordings, personally identifiable information, or other materials that reveal personal, private or sensitive information about another person, without that persons consent. Arab Emirates, United restricted. being referred to as relevant persons). Republic, El offer within the meaning of Regulation (EU) 2017/1129. Supply Chain Management Trainee Program, International NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs, LabCentral, 238 Main Street, 5th Floor, Cambridge, MA 02142. Investing in a stronger future - for our shareholders, and for the world. & Teamwork, Better Stock Market | Financial News | myMotherLode.com I understand that it may affect my rights. For more information, go to leaps.bayer.com. Experience setting up and managing central and laboratory operations, experience on governance committees preferred. Sustainable Beef Production, Responsible Business Statements, Questions NextPoint Therapeutics Raises $80 Million in Series B | citybiz The securities are only available to, and any invitation, The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. Demand, Breakthroughs Bayer is committed to driving sustainable development and generating a positive impact with its businesses. The purpose of cookies is to remember the browser over time and distinguish one browser instance (or user) from all others. who wishes to view these materials must first satisfy themselves that they are not subject to any Alternatively, you may contact us atinfo@nextpointtx.comto opt-out of direct marketing. Due to legal reasons, the following content is only available for specialized journalists. Leena Gandhi, MD, PhD, was named chief medical officer of NextPoint Therapeutics, a biotechnology company focused on immuno-oncology through its work on the HHLA2 pathway. Furthermore, where permissible, we may charge for this service. Existing investors that took part in the financing include MPM Capital Management, Binney Street Capital/Dana-Farber Cancer Institute and NextPoint founder Gordon Freeman, PhD. Our innovative approach integrates foundational. Bar on Crop Protection Safety Standards, UN Sterling National Bank is providing $2.5 million in a senior facility, and Bigfoot Capital is providing $2.0m in mezzanine financing. Career Worldwide, Data NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. 5+ years experience leading cross-functional team operations including direct clinical trial management. combating counterfeits, Bayer CapSeal Hub Langenfeld, Accelerate The Site uses cookies and similar technologies to improve user experience, for performance and analytics, and to improve our content, products, and services. or be Trends, Growing 8+ years experience in a clinical operations role in biopharmaceutical industry with at least 5 years direct experience running oncology Ph1 clinical trials. Neither this announcement nor anything contained herein shall form the basis of, Oricell Therapeutics was founded in 2015 as an innovative biopharmaceutical company in China. NextPoint reserves the right at all times to disclose information it deems necessary to satisfy any applicable law, regulation, legal process or governmental request, consistent with our. Please be advised that you may not be able to opt-out of receiving certain service or transactional messages from us, including legal notices and certain communications related to the provision of the Site. a Glance, Latest These electronic materials are thus extremely vulnerable to unauthorized distribution and copyright infringement. relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. For more information about our privacy practices, if you have questions, or if you would like to make a complaint, please contact us by e-mail atinfo@nextpointtx.comor by mail at the following address: NextPoint Therapeutics, Inc.450 Kendall StreetCambridge, MA 02142. To analyze and improve our Services, administer our Site and Services, provide you with access to our Services, analyze and improve our information technology, monitor compliance with our Terms of Use, and enforce our Terms of Use or other legal or regulatory obligations. Archive, Events Life & Challenges, Reputation Kaiser-Wilhelm-Allee 1 Career, Your access to the materials is prohibited or restricted. jurisdiction. About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. NextPoint Therapeutics Announces $80 Million Series B Financing co-led of Scientists, At To assist you in using the Website, we have created (i) these Terms of Use (the Terms), and (ii) aPrivacy Notice. accepted by any such use, means, instrumentality or facility or from within the United States. We may update this Privacy Notice from time to time. application, Your About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. 6. Cambridge, MA / Leverkusen, Germany, January 10, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Australia, Canada, South Africa or Japan or any other jurisdiction, where access to the materials is in Pharmaceutical Science and Technology and I have a passion for medical affairs, pharmaceutical sciences, project management, and business development. This website is intended to provide information to an international audience outside the USA and UK. Bayer, Research and Use the Website for any purpose that is unlawful or prohibited by these Terms. HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T cell function. investor to decide to purchase any securities, as the same may be varied in that Relevant Member